Natera partnership removes financing risk through 2020, says Piper Jaffray

Piper Jaffray analyst William Quirk says he likes the “non-dilutive funding” from Natera’s 10-year partnership agreement with BGI Genomics and believes the deal removes the company’s financing risk through at least 2020. Further, BGI is a major sequencing provider in China and this deal immediately expands Natera’s access to this large market, Quirk tells investors in a research note. This “looks like a smart deal for both parties,” says Quirk, who reiterates an Overweight rating on Natera with a $23 price target.

https://thefly.com/landingPageNews.php?id=2877245